Concord Biotech Q2FY27 Revenue Up 25% to ₹309 Crore; Launches Dermatology Division
Concord Biotech reported Q2FY27 revenue of ₹309.1 crore, a 25% increase year-on-year. The company launched its new dermatology division, 'Inspira,' and received two ANDA approvals for Tofacitinib and MMF OS. A 1:1 bonus share issue was also approved. Margins were impacted by input costs and product mix changes.
The strong revenue growth, expansion into a new segment (dermatology), ANDA approvals, and bonus share issue are significant developments that are likely to impact the company's market position and shareholder value.
The company reported strong revenue growth, new product launches, and regulatory approvals, along with a bonus share issue, indicating positive performance and future outlook.
Concord Biotech Limited announced its unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The company reported a robust year-on-year revenue growth of 25% in Q2FY27, reaching ₹309.1 crore, driven by broad-based performance across product categories and geographies.
Margins were marginally impacted due to a change in product mix and an increase in raw material prices. The company highlighted that EBITDA margins, excluding specific one-time expenses, stood at 37.1% for Q2FY27. Key achievements during the quarter include the launch of 'Inspira,' a new dermatology division aimed at expanding the company's presence in the dermatology segment with science-led skin solutions. Additionally, Concord Biotech received two ANDA approvals for Tofacitinib and MMF OS, which are expected to increase market reach in US and other regulated markets.
The company also successfully completed global regulatory inspections, including the USFDA inspection at its Unit II formulation facility in Valthera, Ahmedabad, with only one minor procedural observation unrelated to GMP. Reinforcing its commitment to shareholder value, the company approved a 1:1 bonus share issue. Concord Biotech remains confident in delivering sustainable long-term growth, supported by its strong compliance track record, differentiated product portfolio, and expanding customer relationships.
What to do with a filing like this
Concord Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Concord Biotech Limited. Read the original for the full detail.